Medicine shortages are, and have become a complex global issue, creating difficulties for healthcare professionals with risks to patient safety.
Bottom line? People’s lives are being put at risk because of medicine shortages, and there is evidence that shortages are worsening with time.
Effectively planning for, and managing drug shortages remains a challenge due to the varying factors that could result in a shortage. Every shortage is different in size, scope and significance.
Causes are several and multidimensional in the context of a complex global supply chain.
Regardless of this, there is a patient in need somewhere and put at risk because of a medicine shortage.
There is increasing pressure on biopharma to do more to lessen the frequency of drug shortages within their own portfolio.
To assure supply for patient treatments: - Decisive leadership needed to prioritise critical resources when it comes to employees, capital assets and partner networks
Building simulation models that consider inventory levels, demand patterns, and factoring in supplier lead times. This however does not include internal and commercial decision making that is also a contributing factor.
Drug shortages stem from societal values. From the choices and expectations we have from pharmaceutical and biotechnology industries, the regulators and our health services.
There is a moral and political imperative to respond to drug shortages as vigorously as possible in ethically and politically sophisticated ways.
Generic drug market, where price competition is the primary way to gain market share, economic incentives are stacked firmly against investing in plant improvements or redundancies
Institutions and governments may feel compelled to trade-off safety against access by,